10 assets in Common Variable Immunodeficiency

Therapeutic assets addressing Common Variable Immunodeficiency, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Thiotepa Common Variable Immunodeficiency	University of Florida	P2	BB (64)
Alemtuzumab Common Variable Immunodeficiency	Paul Szabolcs	P2	CCC (53)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Common Variable Immunodeficiency	Paul Szabolcs	P2	CCC (53)
Fludarabine Common Variable Immunodeficiency	Paul Szabolcs	P2	CCC (53)
Melphalan Common Variable Immunodeficiency	Paul Szabolcs	P2	CCC (53)
cd3/cd19 negative allogeneic hematopoietic stem cells Common Variable Immunodeficiency	Paul Szabolcs	P1/2	CCC (48)
Busulfanum Common Variable Immunodeficiency	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Cyclophosphamide Common Variable Immunodeficiency	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Common Variable Immunodeficiency	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Igpro20 Common Variable Immunodeficiency	Memorial Sloan Kettering Cancer Center	P2	NR ()